Answers are grounded in this paper and cite their sources.
Patients with early-stage nasopharyngeal cancer are treated with definitive radiotherapy alone, including both sides of the neck and retropharyngeal nodes. For patients with locoregionally advanced nasopharyngeal cancer, the recommendation is concurrent chemoradiotherapy with additional chemotherapy (either before or after chemoradiotherapy). Adding targeted therapies like nimotuzumab to concurrent chemoradiation in the management of nasopharyngeal cancer has been shown to improve overall survival with excellent safety and tolerability.
No takes yet. Share an insight, caveat, or question.
Gairola et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: